Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Our goal is not just a number on the scale
For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]
Realworld data signals and expanding clinical programs suggest potential benefits across cardiovascular risk, certain cancers and immunologic, psychiatric and neurologic endpoints
This product/service is not endorsed by the makers of Ozempic , Wegovy , Mounjaro
GLP-1 medications help lower blood sugar and support weight loss by affecting several processes in the body
doi: 10.3390/antiox9121310 37
